Acelot
Biotechnology, 5385 Hollister Ave Ste 111, Palo Alto, California, 93111, United States, 1-10 Employees
Who is ACELOT
Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are...
Read More
-
Headquarters: 5385 Hollister Ave Ste 111, Palo Alto, California, 93111, United States
-
Date Founded: 2006
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 1799
|
NAICS Code: 238990 |
Show More
Acelot Org Chart and Mapping
Email
Phone
Similar Companies to Acelot
Mantra Bio
-
11-50
-
$ 10 Million to 25 Million
Maze Therapeutics
-
51-200
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Acelot
Answer: Acelot's headquarters are located at 5385 Hollister Ave Ste 111, Palo Alto, California, 93111, United States
Answer: Acelot's official website is https://acelot.com
Answer: Acelot's revenue is $5 Million to $10 Million
Answer: Acelot's SIC: 1799
Answer: Acelot's NAICS: 238990
Answer: Acelot has 1-10 employees
Answer: Acelot is in Biotechnology
Answer: Acelot top competitors include: Mantra Bio , Maze Therapeutics
Answer: Acelot contact info: Phone number: Website: https://acelot.com
Answer: Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinsons, diabetes and cancer. Acelots platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelots first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimers. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month